Seelos Therapeutics, Inc. (SEEL) SEC Filing 8-K Material Event for the period ending Thursday, March 7, 2019

Seelos Therapeutics, Inc.

CIK: 1017491 Ticker: SEEL

View differences made from one to another to evaluate Seelos Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Seelos Therapeutics, Inc..


Assess how Seelos Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Seelos Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Seelos Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: SEEL
CIK: 1017491
Form Type: 8-K Corporate News
Accession Number: 0001136261-19-000099
Submitted to the SEC: Fri Mar 08 2019 6:39:16 AM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Thursday, March 7, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: